POMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare Payment

Building a Four-Tier Revenue Structure Across B2C Services, AI-Enabled Chronic Disease Management, B2B Healthcare Services, and Pharmaceutical RWS/RWD

GUANGZHOU, China, Nov. 4, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an overview of its strategic evolution and business model transformation amid the rapid development of China's digital healthcare industry. Since its establishment in 2010, Pomdoctor has progressively evolved from the industry's early "traffic monetization" model toward a more diversified and value-oriented healthcare ecosystem, culminating in its current four-tier revenue structure spanning B2C healthcare services, AI-enabled chronic disease management, B2B enterprise and hospital services, and pharmaceutical real-world study ("RWS") and real-world data ("RWD") services.

From Traffic Monetization to Diversified Healthcare Services

Pomdoctor was established in 2010, when China's digital healthcare industry was entering an early stage of transformation. At the time, the prevailing business model centered on "traffic monetization," with online consultations and pharmaceutical e-commerce generating revenue primarily through user acquisition, engagement, and pharmaceutical sales. As major participants from the e-commerce and pharmaceutical sectors entered the market, competition intensified, placing increasing pressure on the sustainability and differentiation of this model.

Recognizing the structural limitations of relying primarily on user traffic and pharmaceutical transactions, including patients' limited willingness to pay directly for healthcare services, constrained health insurance coverage, and limitations in advertising-based monetization, Pomdoctor began developing a more diversified business model. The Company expanded beyond a purely service-oriented model and introduced subscription-based offerings supported by more refined operations and specialized healthcare services, establishing an early foundation for recurring and diversified revenue generation.

Expansion into B2B and Hospital Services

As the digital healthcare industry continued to evolve, Pomdoctor further expanded into B2B services, leveraging its healthcare expertise and digital capabilities to provide digital marketing solutions for pharmaceutical companies. Over time, this business evolved from pharmaceutical-focused digital services toward deeper engagement with healthcare institutions, including public hospitals.

This transition enabled Pomdoctor to broaden its role within the healthcare ecosystem, from serving individual users to connecting patients, healthcare providers, pharmaceutical companies, and other enterprise stakeholders. The Company believes this accumulated experience and institutional connectivity have provided an important foundation for its subsequent expansion into higher-value healthcare services.

Leveraging AI and Data to Unlock New Value

With the emergence of artificial intelligence ("AI") as a transformative force across the healthcare industry, Pomdoctor has continued to build on its existing capabilities by developing and piloting AI-enabled healthcare programs with the objective of converting clinical applications into scalable, revenue-generating services. At the same time, the Company's accumulated healthcare data assets have created opportunities for higher-value applications in chronic disease management, pharmaceutical research, and other data-driven healthcare services.

By integrating AI technologies, wearable devices, and its existing digital healthcare infrastructure, Pomdoctor is developing a more integrated ecosystem designed to connect patient services, chronic disease management, healthcare institutions, pharmaceutical companies, and data-driven applications. The Company believes this integrated approach can progressively transform data assets from primarily operational resources into sources of incremental commercial value. The Company's AI-enabled chronic disease subscriptions and pharmaceutical RWS/RWD services are at an early stage of commercialization.

Building a Four-Tier Revenue Structure

Pomdoctor's current business model is structured around four interconnected revenue tiers:

• B2C Basic Healthcare Services — providing an entry point for patients and users through core digital healthcare services;
• AI-Enabled Chronic Disease Membership Subscriptions — extending user relationships through personalized, technology-enabled chronic disease management and recurring subscription services;
• B2B Enterprise and Hospital Services — leveraging the Company's healthcare capabilities and institutional relationships to provide digital solutions and services to enterprises and healthcare institutions; and
• Pharmaceutical RWS/RWD Services — leveraging accumulated healthcare data, clinical experience, and AI capabilities to support pharmaceutical companies in real-world studies ("RWS") and real-world data ("RWD") applications.

Together, these four tiers are designed to create a progressive value chain rather than operate as independent revenue streams. B2C services provide the foundation for patient engagement and healthcare data accumulation; AI-enabled chronic disease subscriptions deepen patient relationships and enhance recurring revenue; B2B enterprise and hospital services broaden the Company's institutional reach and commercial applications; and the resulting data and healthcare infrastructure create a foundation for higher-value pharmaceutical RWS/RWD services.

Pomdoctor believes this interconnected model is designed for longer-term growth opportunities, while creating a potential flywheel effect in which expanding users, healthcare services, institutional relationships, AI applications, and data assets reinforce one another and support the Company's ongoing transition toward more value-based healthcare monetization.

Management Commentary

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "Since our inception, we have continuously sought distinctive and sustainable ways to create value as the healthcare industry evolves through successive waves of business model and technological change. From our early focus on digital healthcare services, to the development of subscription-based offerings and B2B healthcare services, and now to AI-enabled chronic disease management and data-driven pharmaceutical services, we have consistently endeavored to invest ahead of emerging industry trends while building upon our existing capabilities.

"Today, Pomdoctor is focused on further strengthening our four-tier revenue structure and integrating these businesses into a more comprehensive healthcare ecosystem. We believe the combination of healthcare services, AI, institutional capabilities, and data assets provides a scalable foundation for our next stage of growth. With our experience and capabilities in China, we are also exploring opportunities to replicate and adapt this model in key international markets. We remain committed to continuously improving our business model, expanding our ecosystem, and translating our operational capabilities and innovation into sustainable long-term value for our shareholders."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding: the Company's strategic evolution from a traffic monetization model toward value-based healthcare payment and monetization; the Company's plans to further strengthen its four-tier revenue structure spanning B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical RWS/RWD services, and to integrate these businesses into a more comprehensive healthcare ecosystem; the Company's development and piloting of AI-enabled healthcare programs and its ability to convert clinical applications into scalable, revenue-generating services; the Company's plans to integrate AI technologies, wearable devices and its existing digital healthcare infrastructure, and its belief that such integration can progressively transform data assets into sources of incremental commercial value; the Company's expectations regarding growth in recurring subscription revenue, the expansion of its institutional reach and relationships with healthcare institutions, including public hospitals, and pharmaceutical companies, and the development of higher-value pharmaceutical RWS/RWD services; the Company's belief that its interconnected business model is designed to balance near-term revenue generation and cash flow with longer-term growth opportunities and to create a potential flywheel effect; the Company's exploration of opportunities to replicate and adapt its business model in key international markets; and the anticipated benefits of the Company's strategy for patients, healthcare providers, pharmaceutical companies, shareholders and other ecosystem participants, including sustainable long-term value creation. Investors can identify many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "aims," "estimates," "projects," "intends," "plans," "pursues," "positions," "will," "would," "should," "could," "may" or other similar expressions. These forward-looking statements are based on the Company's current expectations, assumptions and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and investors are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements speak only as of the date of this announcement, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, except as may be required by law.

Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors and uncertainties. Investors are urged to review the section entitled "Item 3. Key Information—D. Risk Factors" in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2026, and the Company's other filings with the SEC, which are available on the SEC's website at www.sec.gov.

For more information, please contact:

POMDOCTOR LIMITED

Investor Relations Department

Email: ir@7lk.com

Ascent Investor Relations LLC

Tina Xiao

Phone: +1-646-932-7242

Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-advances-strategic-evolution-from-traffic-monetization-to-value-based-healthcare-payment-302927633.html

SOURCE POMDOCTOR LIMITED